These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

571 related articles for article (PubMed ID: 25682993)

  • 121. Azathioprine is essential following cyclosporine for patients with steroid-refractory ulcerative colitis.
    Miyake N; Ando T; Ishiguro K; Maeda O; Watanabe O; Hirayama Y; Maeda K; Morise K; Matsushita M; Furukawa K; Funasaka K; Nakamura M; Miyahara R; Ohmiya N; Goto H
    World J Gastroenterol; 2015 Jan; 21(1):254-61. PubMed ID: 25574099
    [TBL] [Abstract][Full Text] [Related]  

  • 122. Predictors of endoscopic inflammation in patients with ulcerative colitis in clinical remission.
    Rosenberg L; Lawlor GO; Zenlea T; Goldsmith JD; Gifford A; Falchuk KR; Wolf JL; Cheifetz AS; Robson SC; Moss AC
    Inflamm Bowel Dis; 2013; 19(4):779-84. PubMed ID: 23446338
    [TBL] [Abstract][Full Text] [Related]  

  • 123. Moderate-to-severe Endoscopic Inflammation is Frequent After Clinical Remission in Pediatric Ulcerative Colitis.
    Sarbagili-Shabat C; Weiner D; Wardi J; Abramas L; Yaakov M; Levine A
    J Pediatr Gastroenterol Nutr; 2021 Apr; 72(4):569-573. PubMed ID: 33346576
    [TBL] [Abstract][Full Text] [Related]  

  • 124. Role of Ulcerative Colitis Endoscopic Index of Severity (UCEIS) versus Mayo Endoscopic Subscore (MES) in Predicting Patients' Response to Biological Therapy and the Need for Colectomy.
    Di Ruscio M; Variola A; Vernia F; Lunardi G; Castelli P; Bocus P; Geccherle A
    Digestion; 2021; 102(4):534-545. PubMed ID: 32739919
    [TBL] [Abstract][Full Text] [Related]  

  • 125. In patients with ulcerative colitis, adsorptive depletion of granulocytes and monocytes impacts mucosal level of neutrophils and clinically is most effective in steroid naïve patients.
    Tanaka T; Okanobu H; Yoshimi S; Murakami E; Kogame A; Imagawa H; Numata Y; Kuga Y; Moriya T; Ohya T; Kajiyama G
    Dig Liver Dis; 2008 Sep; 40(9):731-6. PubMed ID: 18387860
    [TBL] [Abstract][Full Text] [Related]  

  • 126. TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis.
    Olsen T; Goll R; Cui G; Christiansen I; Florholmen J
    Cytokine; 2009 May; 46(2):222-7. PubMed ID: 19286392
    [TBL] [Abstract][Full Text] [Related]  

  • 127. Rapid endoscopic improvement is important for 1-year avoidance of colectomy but not for the long-term prognosis in cyclosporine A treatment for ulcerative colitis.
    Kobayashi T; Naganuma M; Okamoto S; Hisamatsu T; Inoue N; Ichikawa H; Takayama T; Saito R; Sujino T; Ogata H; Iwao Y; Hibi T
    J Gastroenterol; 2010 Nov; 45(11):1129-37. PubMed ID: 20614157
    [TBL] [Abstract][Full Text] [Related]  

  • 128. Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis.
    Ochsenkühn T; Tillack C; Szokodi D; Janelidze S; Schnitzler F
    United European Gastroenterol J; 2020 Feb; 8(1):91-98. PubMed ID: 32213052
    [TBL] [Abstract][Full Text] [Related]  

  • 129. Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease.
    af Björkesten CG; Nieminen U; Sipponen T; Turunen U; Arkkila P; Färkkilä M
    Scand J Gastroenterol; 2013 May; 48(5):543-51. PubMed ID: 23477356
    [TBL] [Abstract][Full Text] [Related]  

  • 130. Intravenous tacrolimus is a superior induction therapy for acute severe ulcerative colitis compared to oral tacrolimus.
    Shimizu H; Fujii T; Kinoshita K; Kawamoto A; Hibiya S; Takenaka K; Saito E; Nagahori M; Ohtsuka K; Watanabe M; Okamoto R
    BMC Gastroenterol; 2021 Dec; 21(1):494. PubMed ID: 34949172
    [TBL] [Abstract][Full Text] [Related]  

  • 131. The role of endoscopic assessment in ulcerative colitis in the era of infliximab.
    Daperno M; Sostegni R; Pera A; Rognone D; Rigazio C; Ercole E; Crocellà L; Lavagna A; Rocca R
    Dig Liver Dis; 2008 Jul; 40 Suppl 2():S220-4. PubMed ID: 18598992
    [TBL] [Abstract][Full Text] [Related]  

  • 132. Thiopurine naivety at tacrolimus induction is a predictor of long-term remission in patients with intractable ulcerative colitis who responded to tacrolimus.
    Takatsu N; Hisabe T; Kishi M; Takeda T; Yasukawa S; Koga A; Kinjo K; Hirai F; Ueki T; Yao K
    J Gastroenterol Hepatol; 2023 Jan; 38(1):52-60. PubMed ID: 36128954
    [TBL] [Abstract][Full Text] [Related]  

  • 133. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial.
    Reinisch W; Sandborn WJ; Hommes DW; D'Haens G; Hanauer S; Schreiber S; Panaccione R; Fedorak RN; Tighe MB; Huang B; Kampman W; Lazar A; Thakkar R
    Gut; 2011 Jun; 60(6):780-7. PubMed ID: 21209123
    [TBL] [Abstract][Full Text] [Related]  

  • 134. Efficacy of Rectal Tacrolimus for Induction Therapy in Patients With Resistant Ulcerative Proctitis.
    Lawrance IC; Baird A; Lightower D; Radford-Smith G; Andrews JM; Connor S
    Clin Gastroenterol Hepatol; 2017 Aug; 15(8):1248-1255. PubMed ID: 28286194
    [TBL] [Abstract][Full Text] [Related]  

  • 135. Infliximab is superior to other biological agents for treatment of active ulcerative colitis: A meta-analysis.
    Mei WQ; Hu HZ; Liu Y; Li ZC; Wang WG
    World J Gastroenterol; 2015 May; 21(19):6044-51. PubMed ID: 26019471
    [TBL] [Abstract][Full Text] [Related]  

  • 136. Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year.
    Guidi L; Marzo M; Andrisani G; Felice C; Pugliese D; Mocci G; Nardone O; De Vitis I; Papa A; Rapaccini G; Forni F; Armuzzi A
    Dig Liver Dis; 2014 Nov; 46(11):974-9. PubMed ID: 25096964
    [TBL] [Abstract][Full Text] [Related]  

  • 137. Maintenance treatment with azathioprine in ulcerative colitis: outcome and predictive factors after drug withdrawal.
    Cassinotti A; Actis GC; Duca P; Massari A; Colombo E; Gai E; Annese V; D'Albasio G; Manes G; Travis S; Porro GB; Ardizzone S
    Am J Gastroenterol; 2009 Nov; 104(11):2760-7. PubMed ID: 19623172
    [TBL] [Abstract][Full Text] [Related]  

  • 138. Middle-term prognosis in patients with ulcerative colitis who achieved clinical and endoscopic remission by budesonide rectal foam.
    Naganuma M; Hirai F; Kobayashi K; Watanabe K; Takeuchi K; Aoyama N; Nozawa H; Motoya S; Ohmori T; Harada A; Nagai Y; Abe T; Yamada Y; Inagaki K; Shimizu N; Kanai T; Watanabe M;
    PLoS One; 2019; 14(8):e0220413. PubMed ID: 31381615
    [TBL] [Abstract][Full Text] [Related]  

  • 139. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial.
    Vermeire S; O'Byrne S; Keir M; Williams M; Lu TT; Mansfield JC; Lamb CA; Feagan BG; Panes J; Salas A; Baumgart DC; Schreiber S; Dotan I; Sandborn WJ; Tew GW; Luca D; Tang MT; Diehl L; Eastham-Anderson J; De Hertogh G; Perrier C; Egen JG; Kirby JA; van Assche G; Rutgeerts P
    Lancet; 2014 Jul; 384(9940):309-18. PubMed ID: 24814090
    [TBL] [Abstract][Full Text] [Related]  

  • 140. Development and Validation of a Confocal Laser Endomicroscopy-Based Score for In Vivo Assessment of Mucosal Healing in Ulcerative Colitis Patients.
    Hundorfean G; Chiriac MT; Mihai S; Hartmann A; Mudter J; Neurath MF
    Inflamm Bowel Dis; 2017 Dec; 24(1):35-44. PubMed ID: 29272480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.